000131170 001__ 131170
000131170 005__ 20240209144725.0
000131170 0247_ $$2doi$$a10.2337/dc18-1410
000131170 0248_ $$2sideral$$a110368
000131170 037__ $$aART-2019-110368
000131170 041__ $$aeng
000131170 100__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, M.
000131170 245__ $$aImpaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome
000131170 260__ $$c2019
000131170 5203_ $$aOBJECTIVE: Diabetes prevalence and incidence increase among individuals with hypothyroidism but also among those with hyperthyroxinemia, which seems contradictory. Both high free thyroxine (fT4) and high thyroid-stimulating hormone (TSH) are present in the resistance to thyroid hormone syndrome. A mild acquired resistance to thyroid hormone might occur in the general population and be associated with diabetes. We aimed to analyze the association of resistance to thyroid hormone indices (the Thyroid Feedback Quantile-based Index [TFQI], proposed in this work, and the previously used Thyrotroph T4 Resistance Index and TSH Index) with diabetes. RESEARCH DESIGN AND METHODS: We calculated the aforementioned resistance to thyroid hormone indices based on a U.S. representative sample of 5, 129 individuals =20 years of age participating in the 2007-2008 National Health and Nutrition Examination Survey (NHANES). Also, to approximate TFQI, a U.S.-referenced Parametric TFQI (PTFQI) can be calculated with the spreadsheet formula =NORM.DIST(fT4_cell_in_pmol_per_L, 10.075, 2.155, TRUE)+NORM.DIST(LN(TSH_cell_in_mIU_per_L), 0.4654, 0.7744, TRUE)-1. Outcomes of interest were glycohemoglobin =6.5%, diabetes medication, diabetes-related deaths (diabetes as contributing cause of death), and additionally, in a fasting subsample, diabetes and metabolic syndrome. Logistic and Poisson regressions were adjusted for sex, age, and race/ethnicity. RESULTS: Odd ratios for the fourth versus the first quartile of TFQI were 1.73 (95% CI 1.32, 2.27) (Ptrend = 0.002) for positive glycohemoglobin and 1.66 (95% CI 1.31, 2.10) (Ptrend = 0.001) for medication. Diabetes-related death rate ratio for TFQI being above versus below the median was 4.81 (95% CI 1.01, 22.94) (Ptrend = 0.015). Further adjustment for BMI and restriction to normothyroid individuals yielded similar results. Per 1 SD in TFQI, odds increased 1.13 (95% CI 1.02, 1.25) for diabetes and 1.16 (95% CI 1.02, 1.31) for metabolic syndrome. The other resistance to thyroid hormone indices showed similar associations for diabetes-related deaths and metabolic syndrome. CONCLUSIONS: Higher values in resistance to thyroid hormone indices are associated with obesity, metabolic syndrome, diabetes, and diabetes-related mortality. Resistance to thyroid hormone may reflect energy balance problems driving type 2 diabetes. These indices may facilitate monitoring treatments focused on energy balance.
000131170 536__ $$9info:eu-repo/grantAgreement/EUR/ERDF-ESF/Investing in your future$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-00009$$9info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-01709
000131170 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000131170 590__ $$a16.019$$b2019
000131170 591__ $$aENDOCRINOLOGY & METABOLISM$$b4 / 143 = 0.028$$c2019$$dQ1$$eT1
000131170 592__ $$a6.48$$b2019
000131170 593__ $$aAdvanced and Specialized Nursing$$c2019$$dQ1
000131170 593__ $$aInternal Medicine$$c2019$$dQ1
000131170 593__ $$aEndocrinology, Diabetes and Metabolism$$c2019$$dQ1
000131170 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131170 700__ $$0(orcid)0000-0003-0604-5042$$aMoreno-Franco, B.$$uUniversidad de Zaragoza
000131170 700__ $$0(orcid)0000-0001-9578-6525$$aLou-Bonafonte, J.M.$$uUniversidad de Zaragoza
000131170 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, R.$$uUniversidad de Zaragoza
000131170 700__ $$0(orcid)0000-0002-9887-2629$$aCasasnovas, J.A.$$uUniversidad de Zaragoza
000131170 700__ $$aGuallar-Castillon, P.
000131170 700__ $$aCenarro, A.
000131170 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000131170 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000131170 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000131170 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131170 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000131170 773__ $$g42, 2 (2019), 303-310$$pDiabetes care$$tDiabetes care$$x0149-5992
000131170 787__ $$tSupplementary material$$whttps://doi.org/10.2337/dc18-1410/-/DC1
000131170 8564_ $$s775611$$uhttps://zaguan.unizar.es/record/131170/files/texto_completo.pdf$$yVersión publicada
000131170 8564_ $$s2404891$$uhttps://zaguan.unizar.es/record/131170/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131170 909CO $$ooai:zaguan.unizar.es:131170$$particulos$$pdriver
000131170 951__ $$a2024-02-09-14:44:30
000131170 980__ $$aARTICLE